391 related articles for article (PubMed ID: 24814874)
1. Comparison of the clinical performances of the AdvanSure HPV Screening Real-Time PCR, the Abbott Real-Time High-Risk HPV Test, and the Hybrid Capture High-Risk HPV DNA Test for Cervical Cancer Screening.
Chung HS; Hahm C; Lee M
J Virol Methods; 2014 Sep; 205():57-60. PubMed ID: 24814874
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the AdvanSure human papillomavirus screening real-time PCR, the Abbott RealTime High Risk human papillomavirus test, and the Hybrid Capture human papillomavirus DNA test for the detection of human papillomavirus.
Hwang Y; Lee M
Ann Lab Med; 2012 May; 32(3):201-5. PubMed ID: 22563555
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the analytical and clinical performances of Abbott RealTime High Risk HPV, Hybrid Capture 2, and DNA Chip assays in gynecology patients.
Park S; Kang Y; Kim DG; Kim EC; Park SS; Seong MW
Diagn Microbiol Infect Dis; 2013 Aug; 76(4):432-6. PubMed ID: 23791386
[TBL] [Abstract][Full Text] [Related]
4. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test.
Poljak M; Kovanda A; Kocjan BJ; Seme K; Jancar N; Vrtacnik-Bokal E
Acta Dermatovenerol Alp Pannonica Adriat; 2009 Sep; 18(3):94-103. PubMed ID: 19784522
[TBL] [Abstract][Full Text] [Related]
5. Comparison of clinical performances among Roche Cobas HPV, RFMP HPV PapilloTyper and Hybrid Capture 2 assays for detection of high-risk types of human papillomavirus.
Yu S; Kwon MJ; Lee EH; Park H; Woo HY
J Med Virol; 2015 Sep; 87(9):1587-93. PubMed ID: 25914215
[TBL] [Abstract][Full Text] [Related]
6. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Abbott RealTime High Risk HPV and Hybrid Capture 2 for the detection of high-risk HPV DNA in a referral population setting.
Venturoli S; Leo E; Nocera M; Barbieri D; Cricca M; Costa S; Santini D; Zerbini M
J Clin Virol; 2012 Feb; 53(2):121-4. PubMed ID: 22115872
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a new multiplex real-time polymerase chain reaction assay for the detection of human papillomavirus infections in a referral population.
Jentschke M; Soergel P; Lange V; Kocjan B; Doerk T; Luyten A; Petry KU; Poljak M; Hillemanns P
Int J Gynecol Cancer; 2012 Jul; 22(6):1050-6. PubMed ID: 22740006
[TBL] [Abstract][Full Text] [Related]
9. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.
Carozzi F; Bisanzi S; Sani C; Zappa M; Cecchini S; Ciatto S; Confortini M
J Clin Microbiol; 2007 Feb; 45(2):364-9. PubMed ID: 17122008
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a multiplex real time PCR assay for the detection of human papillomavirus infections on self-collected cervicovaginal lavage samples.
Jentschke M; Soergel P; Hillemanns P
J Virol Methods; 2013 Oct; 193(1):131-4. PubMed ID: 23707925
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers.
Basu P; Banerjee D; Mittal S; Dutta S; Ghosh I; Chowdhury N; Abraham P; Chandna P; Ratnam S
J Med Virol; 2016 Jul; 88(7):1271-8. PubMed ID: 26693677
[TBL] [Abstract][Full Text] [Related]
12. Detection and genotyping of human papillomavirus by five assays according to cytologic results.
Choi J; Park Y; Lee EH; Kim S; Kim JH; Kim HS
J Virol Methods; 2013 Jan; 187(1):79-84. PubMed ID: 22982075
[TBL] [Abstract][Full Text] [Related]
13. The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies.
Poljak M; Oštrbenk A
Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(2):43-7. PubMed ID: 23836358
[TBL] [Abstract][Full Text] [Related]
14. Comparison Study of BD Onclarity HPV With digene HC2 High-Risk HPV DNA Test and Roche Cobas 4800 HPV for Detecting High-Risk Human Papillomavirus in Japan.
Nakamura M; Nakade K; Orisaka S; Iwadare J; Mizumoto Y; Fujiwara H
Am J Clin Pathol; 2019 Feb; 151(3):263-269. PubMed ID: 30260388
[TBL] [Abstract][Full Text] [Related]
15. Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology.
Huang S; Erickson B; Tang N; Mak WB; Salituro J; Robinson J; Abravaya K
J Clin Virol; 2009 Jul; 45 Suppl 1():S19-23. PubMed ID: 19651364
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of the effectiveness of BMRT-HPV for cervical cancer screening].
Duan LF; Du H; Wang C; Huang X; Qu XF; Duan XZ; Liu Y; Shi B; Zhang W; Wei LH; Belinson L; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2020 Oct; 55(10):708-715. PubMed ID: 33120484
[No Abstract] [Full Text] [Related]
17. [Performance of human papillomavirus typing test in cervical precancer lesions and cervical cancer screening].
Zhang SK; Luo XP; Li ZF; Su Z; Xia JC; Hu GY; Zhu YJ; Xie LX; Feng XX; Sun XB; Chen W; Qiao YL
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):252-256. PubMed ID: 32252206
[No Abstract] [Full Text] [Related]
18. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
19. Clinical Validation of Anyplex II HPV HR Detection Test for Cervical Cancer Screening in Korea.
Jung S; Lee B; Lee KN; Kim Y; Oh EJ
Arch Pathol Lab Med; 2016 Mar; 140(3):276-80. PubMed ID: 26927723
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of gene chip technology for high risk type human papillomavirus in cervical cancer screening].
Li RZ; Shi JF; Zhou QZ; Wu RF; Li N; Wu LN; Zhou YQ; Wang Q; Liu ZH; Liu B; Qiao YL
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(5):307-11. PubMed ID: 16677522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
